USD $1.00-10.00 / Kilogram
lorcaserin(856681-05-5)is an orally administered agent and a selective 5-ht2c receptor agonist for the treatment of obesity. it had been approved for marketing in us by fda on 27 june in 2012. in clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
gefitinib basic information |
product name: | gefitinib |
synonyms: | iressa;gefitinib;akos 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;zd 1839;4-quinazolinamine, n-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;gefitinib(tinibs) |
cas: | 184475-35-2 |
mf: | c22h24clfn4o3 |
mw: | 446.9 |
einecs: | |
product categories: | active pharmaceutical ingredients;gefitinib;molecular targeted antineoplastic;intermediates & fine chemicals;pharmaceuticals;pharmaceutical intermediate;apis;iressa;anti-cancer&immunity;api;inhibitors;anticancer |
mol file: | 184475-35-2.mol |
gefitinib chemical properties |
melting point | 119-1200c |
storage temp. | store at rt |
cas database reference | 184475-35-2(cas database reference) |